Aprea Therapeutics
APRE
21 hedge funds and large institutions have $3.66M invested in Aprea Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
32% more capital invested
Capital invested by funds: $2.78M → $3.66M (+$884K)
11% more funds holding
Funds holding: 19 → 21 (+2)
0.18% less ownership
Funds ownership: 23.64% → 23.46% (-0.18%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.2K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$11.9K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$707 |
| 4 |
BOC
Bull Oak Capital
San Diego,
California
|
+$142 |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$91 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$41.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$22.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.75K |
| 4 |
Morgan Stanley
New York
|
-$2.63K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$148 |
APRE Hedge Fund Activity: Q3 2023 in Review
21 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q3 2023, worth a combined $3.66M — up 32% from $2.78M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new APRE positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $43.2K. The largest seller was Walleye Capital, cutting an estimated $41.1K.
- 21 institutional investors held Aprea Therapeutics (APRE) as of Q3 2023, up from 19 in Q2 2023.
- Funds reported $3.66M of Aprea Therapeutics stock for Q3 2023, up 32% quarter-over-quarter.
- 4 funds opened new Aprea Therapeutics positions in Q3 2023 and 1 closed out, a net change of +3 holders.
- The largest Aprea Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $43.2K added.
- The largest Aprea Therapeutics seller in Q3 2023 was Walleye Capital, an estimated $41.1K sold.
Based on aggregated 13F filings for Q3 2023.